AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 22 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - NYVAC(K1L)-HA is the first attenuated live viral vector that is capable of inducing adultlike antibody, Th1, and cytotoxic T lymphocyte (CTL) responses against measles in young mice, researchers at the WHO Collaborating Center for Neonatal Vaccinology have found.
"Although initially developed in adult animals, novel viral vectors expressing recombinant measles antigens must eventually prove their success in the early life setting, where the efficacy of the currently used live-attenuated measles virus vaccine is limited," wrote J. Kovarik and colleagues in Virology.
Newborns are less able than adults to generate Th1 and CTL responses, as well as protective antibodies, pointed out Kovarik and coworkers.
They found that young BALB/c mice immunized with a single dose of a vaccinia-based NYVAC(K1L) vector could generate adult-like antihemagglutinin (HA) antibody responses as well as adultlike Th1 and CTL responses.
A prime-boost regimen was necessary to maintain protection; however, since antibody responses (but not T-cell responses) to a single dose of NYVAC(K1L)-HA could be weakened by pre-existing measles antibodies, said Kovarik and team ("Induction of adult-like antibody, Th1, and CTL responses to measles ...
Source: HighBeam Research, Viral Vector Stimulates CTL, Th1 Responses In Young Mice.(Brief...